MURIANNI, VERONICA
 Distribuzione geografica
Continente #
EU - Europa 334
Totale 334
Nazione #
IT - Italia 334
Totale 334
Città #
Genova 113
Genoa 112
Rapallo 107
Bordighera 2
Totale 334
Nome #
The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with Radium-223: A proof of concept study 97
802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study 64
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study) 42
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 37
Novel emerging molecular targets in non-small cell lung cancer 30
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study 24
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study 16
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report 13
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score 9
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program 9
Reliability of patient-reported toxicities during adjuvant chemotherapy 7
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study) 1
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 1
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9) 1
Totale 351
Categoria #
all - tutte 2.158
article - articoli 2.158
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.316


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202177 0 0 2 1 19 33 2 1 4 3 8 4
2021/202243 1 0 3 3 1 1 0 8 7 4 5 10
2022/2023130 7 10 0 17 17 12 5 17 14 4 24 3
2023/2024101 6 8 4 15 7 37 6 3 5 10 0 0
Totale 351